Early on, Biocare recognized the market need for evaluating morphologically distinct markers to aid in solving complex clinical problems and simplifying interpretation, all while conserving precious patient tissue. The most glaring clinical need was determined to be the ability to differentiate between prostatic intraepithelial neoplasia (PIN) and carcinoma of the prostate. There also needed to […]
12
Jul
Jul
According to Fixation on Histology, Biocare Medical’s Dr. Jason Ramos, Ph.D. was awarded one of the top 5 best presentations at NSH 2018. For full details read below! “NSH’s Symposium/Convention is the largest histology conference in the United States with over 100 workshops, an exhibit hall, and plenty of opportunity to network with fellow histologists. […]
Immunohistochemical staining for programmed cell-death ligand 1 (PD-L1) in malignant thymoma and thymic carcinoma. Alexei Shimanovsky, Richard Cartun, Mary Fiel-Gan, Daniza Mandich, Jonathan Earle, Andrew L. Salner… Abstract e20003 Background: Recent development of anti-PD-1/L1 antibodies has demonstrated activity in various neoplasms. Thymic malignancies (TMS) are rare and treatment in advanced disease is limited. To evaluate […]
Excellere Partners has made an investment in Pacheco, California-based Biocare Medical, a provider of immunohistochemistry instrumentation, as well as a full range of reagents for IHC and molecular testing. No financial terms were disclosed. PRESS RELEASE Denver, CO, August 25, 2017 – Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, […]
Concord, CA, August 27, 2015 – Biocare Medical is proud to announce the availability of CK HMW + p63 + AMACR (RM) as an IVD double-stain for Multiplex IHC™. This patented antibody cocktail may be useful in the evaluation of normal prostate glands, prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma (1,2). Previously, this product was […]
Biocare Medical, LLC is pleased to announce that the acquisition of New Windsor, NY based CymoGen Dx, LLC has been finalized. “We are very excited to be adding the portfolio of FISH [Fluorescent in situ Hybridization] probes from CymoGen Dx to our ever-expanding offerings in the Molecular Diagnostic arena,” said Roy Paxton Yih, President & […]
Biocare Medical, LLC has been awarded United States Patent No. US 8,852,592 for the anti-PAX8 mouse monoclonal antibody, clone [BC12]. This mouse monoclonal PAX8 antibody [BC12] has been designed to target a restricted epitope and exhibits higher specificity and provides sharper staining than the PAX8 rabbit polyclonal antibody. This clone was developed in-house and is […]
Concord, California, October 3, 2014 – Biocare Medical, LLC is proud to announce that they have entered into an agreement to acquire New Windsor, NY based CymoGen Dx, LLC. “CymoGen’s broad product line of Next-Gen™ FISH [Fluorescent in situ Hybridization] probes for detection of genetic anomalies in tissue samples adds to Biocare’s growing presence in the Molecular Diagnostics […]
ERG Monoclonal Antibody [9FY] Patent issued to the Uniformed Services University of the Health Sciences Center for Prostate Disease Research & Biocare Medical Concord, CA, August 21, 2014 – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) […]
Concord, CA, July 17, 2014 – Biocare Medical is proud to announce that the United States Patent and Trademark Office has issued US Patent 8,603,765 to Biocare Medical for its PIN-4™ (CK5/14 + P63 + P504S) Multiplex immunohistochemistry (IHC) technology. The PIN-4 antibody cocktail of P504S + p63 + High Molecular Weight Cytokeratin permits the […]